Published in Gene Ther on March 01, 2000
Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol (2003) 3.29
Flexibility of the adenovirus fiber is required for efficient receptor interaction. J Virol (2003) 1.49
Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol (2002) 1.39
The insulin-like growth factor (IGF)-I E-peptides modulate cell entry of the mature IGF-I protein. Mol Biol Cell (2009) 1.05
Correct capsid assembly mediated by a conserved YXXLGL motif in prototype foamy virus Gag is essential for infectivity and reverse transcription of the viral genome. J Virol (2007) 1.00
Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence. J Virol (2002) 0.95
Dynamics of viral and proviral loads of feline immunodeficiency virus within the feline central nervous system during the acute phase following intravenous infection. J Virol (2003) 0.89
MHC mismatch results in neural progenitor cell rejection following spinal cord transplantation in a model of viral-induced demyelination. Stem Cells (2012) 0.89
Assessment of Artificial MiRNA Architectures for Higher Knockdown Efficiencies without the Undesired Effects in Mice. PLoS One (2015) 0.82
Multiple modifications allow high-titer production of retroviral vectors carrying heterologous regulatory elements. J Virol (2004) 0.81
Pharmacogenetic heterogeneity of transgene expression in muscle and tumours. BMC Pharmacol (2003) 0.80
Influence of vector design and host cell on the mechanism of recombination and emergence of mutant subpopulations of replicating retroviral vectors. BMC Mol Biol (2009) 0.78
The U3 region of Moloney murine leukemia virus contains position-independent cis-acting sequences involved in the nuclear export of full-length viral transcripts. J Biol Chem (2014) 0.77
Genetic heterogeneity in response to adenovirus gene therapy. BMC Mol Biol (2003) 0.75
Proviral load determination of different feline immunodeficiency virus isolates using real-time polymerase chain reaction: influence of mismatches on quantification. Electrophoresis (1999) 2.09
The v-mos and H-ras oncogene expression represses glucocorticoid hormone-dependent transcription from the mouse mammary tumor virus LTR. EMBO J (1986) 1.41
Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression. J Gen Virol (1998) 1.36
Production of mouse mammary tumor virus upon transfection of a recombinant proviral DNA into cultured cells. Virology (1985) 1.23
Current perspectives in the biology of mouse mammary tumour virus. Virus Res (1987) 1.19
The chromosomal integration site determines the tissue-specific methylation of mouse mammary tumour virus proviral genes. EMBO J (1984) 1.17
Endogenous superantigen expression controlled by a novel promoter in the MMTV long terminal repeat. Nature (1993) 1.09
A modified procedure for replica plating of mammalian cells allowing selection of clones based on gene expression. Biotechniques (1992) 1.09
Influence of preassay and sequence variations on viral load determination by a multiplex real-time reverse transcriptase-polymerase chain reaction for feline immunodeficiency virus. J Acquir Immune Defic Syndr (2001) 1.07
Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet (2001) 1.06
A mammary-specific promoter directs expression of growth hormone not only to the mammary gland, but also to Bergman glia cells in transgenic mice. Mol Endocrinol (1991) 1.03
Factors controlling the expression of mouse mammary tumour virus. Biochem J (1992) 1.02
CrFK feline kidney cells produce an RD114-like endogenous virus that can package murine leukemia virus-based vectors. J Virol (1998) 1.01
Targeting of retroviral vectors for gene therapy. Hum Gene Ther (1993) 0.97
Spleen specific expression of an MMTV related transcript associated with the Mtv-6 locus in BALB/c mice. Virology (1986) 0.96
Expression of antimicrobial peptides has an antitumour effect in human cells. Biochem Biophys Res Commun (1998) 0.96
Mouse mammary tumor virus mediated transfer and expression of neomycin resistance to infected cultured cells. Virology (1986) 0.95
Rapid and sensitive detection of enhanced green fluorescent protein expression in paraffin sections by confocal laser scanning microscopy. Histochem J (2000) 0.93
naf, a trans-regulating negative-acting factor encoded within the mouse mammary tumor virus open reading frame region. J Virol (1990) 0.92
Virus vector design in gene therapy. Mol Med Today (1995) 0.91
Construction and characterization of a packaging cell line for MMTV-based conditional retroviral vectors. Biochem Biophys Res Commun (1989) 0.90
The endogenous mouse mammary tumour virus locus Mtv-8 contains a defective envelope gene. Virus Res (1986) 0.89
Cell targeting by murine retroviral vectors. Crit Rev Oncol Hematol (1998) 0.89
Rapid identification of viable retrovirus-transduced cells using the green fluorescent protein as a marker. Gene Ther (1997) 0.88
Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies. Hum Gene Ther (2000) 0.87
Mouse mammary tumour virus: a proviral gene contributes to the understanding of eukaryotic gene expression and mammary tumorigenesis. J Gen Virol (1985) 0.86
Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther (1998) 0.84
Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors. Blood (2001) 0.84
Retroviral vectors directed to predefined cell types for gene therapy. Biologicals (1995) 0.84
Development of cellulose sulfate-based polyelectrolyte complex microcapsules for medical applications. Ann N Y Acad Sci (1999) 0.84
The methylation pattern of endogenous mouse mammary tumor virus proviral genes is tissue specific and stably inherited. Virology (1984) 0.84
Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain. Gene Ther (2007) 0.82
Xenotransplantation: is the risk of viral infection as great as we thought? Mol Med Today (2000) 0.82
Expression of anti-sense mRNA in H-ras transfected NIH/3T3 cells does not suppress the transformed phenotype. Gene (1986) 0.82
A transient assay for gene expression studies in B lymphocytes and its use for superantigen assays. Biotechniques (1994) 0.82
Negative-acting factor and superantigen are separable activities of the mouse mammary tumor virus long terminal repeat. Proc Natl Acad Sci U S A (1995) 0.81
Characterization of a human cell clone expressing cytochrome P450 for safe use in human somatic cell therapy. Ann N Y Acad Sci (1999) 0.81
Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study. J Mol Med (Berl) (1999) 0.81
Intraarterial instillation of microencapsulated cells in the pancreatic arteries in pig. Ann N Y Acad Sci (1999) 0.80
The significance of retroviruses in oncology. Onkologie (1990) 0.80
Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide. Cancer Gene Ther (2001) 0.80
Protection of MLV vector particles from human complement. Biochem Biophys Res Commun (1999) 0.80
On the generation of diversity in endogenous superantigens. Immunol Today (1994) 0.79
Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy. Adv Exp Med Biol (1998) 0.79
Retroviral vector targeting for gene therapy. Cytokines Mol Ther (1996) 0.79
Genetic reshuffling reconstitutes functional expression cassettes in retroviral vectors. J Gene Med (2001) 0.79
Inducible expression of p21WAF-1/CIP-1/SDI-1 from a promoter conversion retroviral vector. J Mol Med (Berl) (1998) 0.79
Systemic long-term delivery of antibodies in immunocompetent animals using cellulose sulphate capsules containing antibody-producing cells. Gene Ther (1998) 0.79
Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine. Cancer Gene Ther (2000) 0.79
Effect of simian virus large T antigen expression on cell cycle control and apoptosis in rat pleural mesothelial cells exposed to DNA damaging agents. Oncogene (1998) 0.78
Construction of retroviral vectors for targeted delivery and expression of therapeutic genes. Leukemia (1995) 0.78
Conditional expression of human TNF-alpha: a system for inducible cytotoxicity. Int J Cancer (1994) 0.78
Construction and characterization of a hybrid mouse mammary tumor virus/murine leukemia virus-based retroviral vector. J Virol (1998) 0.78
Expression of the oncogenes mil and ras abolishes the in vivo differentiation of mammary epithelial cells. Carcinogenesis (1988) 0.78
Sub-retroviral particles as gene transfer vectors that by-pass retrovirus-receptor interaction restrictions. Biochem Mol Biol Int (1993) 0.77
Development of retroviral vectors as safe, targeted gene delivery systems. J Mol Med (Berl) (1996) 0.77
Expression of proviral DNA of mouse mammary tumour virus and its transcriptional control sequences. Oxf Surv Eukaryot Genes (1984) 0.77
Needle injection catheter delivery of the gene for an antibacterial agent inhibits neointimal formation. Gene Ther (1999) 0.77
Novel clinical strategies for the treatment of pancreatic carcinoma. Trends Mol Med (2001) 0.77
In vivo perivascular implantation of encapsulated packaging cells for prolonged retroviral gene transfer. J Microencapsul (2001) 0.77
Mapping of a mouse mammary tumor virus integration site by retroviral LTR--arbitrary polymerase chain reaction. Virus Res (1998) 0.76
Identification of three human sequences with viral superantigen-specific primers. Mamm Genome (1995) 0.76
Modulation of Moloney leukemia virus long terminal repeat transcriptional activity by the murine CD4 silencer in retroviral vectors. Virology (2000) 0.76
Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors. Ann N Y Acad Sci (1999) 0.76
Superantigen expression is driven by both mouse mammary tumor virus long terminal repeat-associated promoters in transgenic mice. J Virol (2000) 0.76
A functional eukaryotic promoter is contained within the first intron of the hGH-N coding region. Biochem Biophys Res Commun (1998) 0.75
Changes in selected subpopulations of lymphocytes in dogs infected with Babesia canis treated with imidocarb. Tierarztl Prax Ausg K Kleintiere Heimtiere (2015) 0.75